Literature DB >> 11300494

Suppressed T-cell receptor zeta chain expression and cytokine production in pancreatic cancer patients.

J Schmielau1, M A Nalesnik, O J Finn.   

Abstract

Suppression of various functions of T cells derived from cancer patients has been linked previously to changes in the T-cell receptor (TCR)-associated signal transduction molecules, in particular the zeta chain of the TCR complex. In this study, we have examined the TCRzeta chain expression and cytokine production in vivo and in vitro in T cells of patients with metastatic adenocarcinomas of the pancreas that participated in a Phase I clinical trial of the MUC1 peptide plus bacillus Calmette-Guerin cancer vaccine. A majority of the patients had reduced TCRzeta chain expression and interleukin 4 production by T cells, and all of the patients showed decreased production of IFN-gamma of their peripheral T cells when compared with healthy individuals. Peripheral blood T cells were activated with the phorbol ester phorbol myrisate acetate and ionomycin to show that although aberrant TCRzeta chain expression and decreased cytokine production were often correlated, the reduced cytokine production was not simply a consequence of an impaired TCRzeta chain expression. Rather, these are two separate but parallel defects in signal transduction in T cells, which are potentially modulated by the same mechanisms. Half of the patients showed an improvement for TCRzeta chain or IFN-gamma expression after vaccination.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11300494

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  18 in total

Review 1.  The dawn of vaccines for cancer prevention.

Authors:  Olivera J Finn
Journal:  Nat Rev Immunol       Date:  2017-12-27       Impact factor: 53.106

2.  Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth.

Authors:  Matthew R Porembka; Jonathan B Mitchem; Brian A Belt; Chyi-Song Hsieh; Hyang-Mi Lee; John Herndon; William E Gillanders; David C Linehan; Peter Goedegebuure
Journal:  Cancer Immunol Immunother       Date:  2012-01-04       Impact factor: 6.968

Review 3.  Cancer immunoediting from immune surveillance to immune escape.

Authors:  Ryungsa Kim; Manabu Emi; Kazuaki Tanabe
Journal:  Immunology       Date:  2007-03-26       Impact factor: 7.397

Review 4.  Human tumor antigens, immunosurveillance, and cancer vaccines.

Authors:  Olivera J Finn
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

5.  Alterations of MUC1 and MUC3 expression in gastric carcinoma: relevance to patient clinicopathological features.

Authors:  R-Q Wang; D-C Fang
Journal:  J Clin Pathol       Date:  2003-05       Impact factor: 3.411

Review 6.  Host response in tumor diagnosis and prognosis: importance of immunologists and pathologists alliance.

Authors:  Olivera J Finn
Journal:  Exp Mol Pathol       Date:  2012-10-23       Impact factor: 3.362

Review 7.  Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages.

Authors:  Stefano Ugel; Francesco De Sanctis; Susanna Mandruzzato; Vincenzo Bronte
Journal:  J Clin Invest       Date:  2015-09-01       Impact factor: 14.808

8.  Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14⁻/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer.

Authors:  Chien-Ying Liu; Yu-Min Wang; Chih-Liang Wang; Po-Hao Feng; How-Wen Ko; Yun-Hen Liu; Yi-Cheng Wu; Yen Chu; Fu-Tsai Chung; Chih-Hsi Kuo; Kang-Yun Lee; Shu-Min Lin; Horng-Chyuan Lin; Chun-Hua Wang; Chih-Teng Yu; Han-Pin Kuo
Journal:  J Cancer Res Clin Oncol       Date:  2010-01       Impact factor: 4.553

9.  Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes.

Authors:  Paulo C Rodriguez; Marc S Ernstoff; Claudia Hernandez; Michael Atkins; Jovanny Zabaleta; Rosa Sierra; Augusto C Ochoa
Journal:  Cancer Res       Date:  2009-02-05       Impact factor: 12.701

10.  A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors.

Authors:  Andrew J Lepisto; Arthur J Moser; Herbert Zeh; Kenneth Lee; David Bartlett; John R McKolanis; Brian A Geller; Amy Schmotzer; Douglas P Potter; Theresa Whiteside; Olivera J Finn; Ramesh K Ramanathan
Journal:  Cancer Ther       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.